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Abstract 19 
We artificially infected Sprague Dawley (SD) rats and Kunming (KM) mice with type II Toxoplasma 20 
gondii (T. gondii) strain Prugniaud (Pru) to generate toxoplasmosis, which is a fatal disease mediated 21 
by T. gondii invasion of the central nervous system (CNS) by unknown mechanisms. We aimed to 22 
explore the mechanism of differential susceptibility of mice and rats to T. gondii infection. Therefore, 23 
we established a strategy of isobaric tags for relative and absolute quantitation (iTRAQ) to identify 24 
differentially expressed proteins (DEPs) in the rats’ and the mice’s brains compared to the healthy 25 
groups. Complement component 3 (C3) was upregulated and the tight junction (TJ) pathway showed 26 
a disorder in KM mice, which was susceptible to T. gondii infection. In the CNS, we presumed that 27 
T. gondii-stimulated C3 disrupts the TJ of the blood-brain barrier (BBB). This effect allows more T. 28 
gondii passing to the brain through the intercellular space. 29 
Statement of significance of the study 30 
Rat and mouse models for T. gondii infection are proper pathophysiological models to study the 31 
toxoplasma encephalopathy, and the consequent severe mental disorders, because these two animals 32 
have different susceptibility to T. gondii infection. To explore the reason for this difference, we 33 
analyzed the cerebral proteome in rats and mice during chronic T. gondii infection. Interestingly, our 34 
results underlined alterations of complement and coagulation cascades, and tight junction pathways 35 
in the mouse brain. Specifically, we evaluated the relationship between C3 and TJ during T. gondii 36 
infection, which supports the paracellular entry mechanism.  37 
Keywords: Blood-brain barrier; Central nervous system; Complement component 3; Toxoplasma 38 
gondii; Paracellular entry mechanism 39 
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1. Introduction 40 
Toxoplasma gondii (T. gondii), a critical zoonotic parasite, infects almost all warm-blooded animals, 41 
including human-beings, worldwide[1]. The infection rates of this parasite are estimated at 30% in 42 
humans, but it geographically differs from region to region[2, 3]. Because the most severe 43 
complications occur due to infection of the central nervous system (CNS)[4], it is important to 44 
elucidate how T. gondii transits across the blood-brain barrier (BBB) and enters into the CNS. 45 
Previous studies have reported two primary mechanisms explaining how T. gondii goes through the 46 
BBB, including Trojan-horse like mechanism and a transcellular crossing mechanism[5, 6]. 47 
 48 
T. gondii invades the host cells and persists as intraneuronal cysts, resulting in damage to the CNS in 49 
varying degrees, because the parasites are suppressed by the immune system but not eliminated[7]. 50 
Rats and mice are widely used as experimental animals for T. gondii infection due to their different 51 
susceptibility[8, 9]. Specifically, adult rats have an innate resistance to T. gondii[10]. Tissue infections 52 
induced by cysts appeared in a subclinical form in the immunocompetent rats, though they were 53 
infected with the RH strain (type I genotype)[9]. On the other hand, mice died when infected with type 54 
I genotype strains, irrespective of the infective dose[10]. Compared to type I stains, types II and III 55 
strains are less virulent to mice, and the infective doses of those strains are significantly higher for 56 
rats than for mice, irrespective of the administration routes[11]. Moreover, the T. gondii cysts are 57 
abundantly found in the brains of mice but infrequently found in the brains of rats[9, 12]. In agreement 58 
the rat brain has lower risk of T. gondii infection, with no visible histological damage[12, 13]. Compared 59 
to rats, the learning capacity of mice is much more conspicuously retarded by a T. gondii-infection[14]. 60 
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However, at present, no research has been performed on this kind of difference, and the exact 61 
mechanism is still poorly understood.  62 
 63 
Our goal was to explore the mechanisms of the different susceptibility of mice and rats to T. gondii. 64 
Comparing to control groups, we established an iTRAQ-based strategy to identify differentially 65 
expressed proteins (DEPs) of infected Sprague Dawley (SD) rats and Kun Ming (KM) mice brains. 66 
Afterwards, we used KEGG pathways to analyze the DEPs patterns. Interestingly, in mice brain, we 67 
identified two specific pathways: the complement and coagulation cascades pathway and the tight 68 
junction (TJ) pathway, related to the host immune system and the brain intrusion of T. gondii, 69 
respectively. The two pathways contained 9 and 10 significant DEPs, among them the complement 70 
component 3 (C3), whose expression was increased 11 times. We hypothesize that C3 mediates the 71 
differences in this parasite-host interaction mechanism through disrupting TJ of the BBB to allow T. 72 
gondii invasion of the brain. Repression of the pharmacology or genetics may reduce the damage in 73 
the host, suggesting a therapeutic opportunity. 74 
 75 
2. Materials and Methods 76 
2.1 Animals and Parasites 77 
The SD rats and KM mice were purchased from the Guangdong Medical Laboratory Animal Center, 78 
and were bred under specific pathogen-free conditions at South China Agricultural University. 79 
Parasites were harvested from the brains of KM mice that had been chronically infected with the Pru 80 
strain (preserved in our laboratory), a type II strain of T. gondii. The brain tissue of these animals was 81 
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dispersed in normal saline. The final concentration of the infectious agent was adjusted to a dose of 82 
10 cysts/0.2 ml for mice and a dose of 50 cysts/0.5 ml for rats [11, 13], which were administered orally 83 
by gavage. 84 
 85 
2.2 Sample collection for quantitative proteomic analysis 86 
In total, 18 SPF KM mice (9 males, 9 females, 56 days old), and 9 SPF rats (4 males, 5 females, 60 87 
days old) were infected with type II T. gondii Pru strain, and were randomly divided into 3 groups. 88 
Each group contained 6 mice and 3 rats. After 30 days of infection, we collected brain tissue from 89 
the infected KM mice and rats. Simultaneously, we collected brain tissue from 18 uninfected KM 90 
mice and 9 uninfected rats at similar age and sex to serve as uninfected control group. Each of the 91 
brain tissue samples was divided into 3 equal parts; two parts were processed for proteomics analysis 92 
(one as the biological replicate, the other as the technical replicate), while the last part was used for 93 
qRT-PCR validation. All animal care procedures were conducted in conformity with NIH guidelines 94 
(NIH Pub. No. 85-23, revised 1996) and were approved by the Animal Ethics Committee of South 95 
China Agricultural University (SCAUAEC-2015-054).  96 
 97 
Using a mortar and pestle, 100 mg brain tissue from each animal was ground into a fine powder and 98 
preserved in liquid nitrogen. Then, we used the Radio immunoprecipitation assay (RIPA) Lysis Buffer 99 
(50mM Tris-HCl, 150mM Nacl, 1% SDS, 1% SDC pH 8.0, 0.1% Triton X-100) to extract total 100 
proteins from each sample. The samples were sonicated (20 Watts, 10 times) and centrifuged (4ºC, 101 
12,000 rpm, 20 min).  102 
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 103 
2.3 Trypsin digestion and iTRAQ labeling 104 
We used the BCA method (BCA Protein Assay Kit, Biotech) to determine the protein 105 
concentrations[15], and utilized the filter-aided sample preparation (FASP) method to digest 106 
proteins[16]. Briefly, we reduced the alkylated, and subjected it to the tryptic hydrolysis of each protein 107 
sample (100 μg). iTRAQ labeling was performed according to manufacturer’s protocol (Applied 108 
Biosystems, Sciex). The samples of infected micewere labeled with iTRAQ tag 114 and 115, while 109 
the samples of control mice were labeled with tag 113 and 116. The samples of infected rats were 110 
labeled with iTRAQ tag 119 and 121, while the samples of control rats were labeled with tag 117 and 111 
118. All labeled samples were pooled together and vacuum-dried. 112 
 113 
2.4 High-pH Reversed-Phase Chromatography 114 
We carried out a high pH Reverse Phase Fractionation (hpRP) chromatography using a Dionex 115 
UltiMate 3000 high-performance Liquid Chromatography (LC) system, whose autosampler and 116 
ultraviolet (UV) detection was equipped with collection option of the micro fraction. We diluted the 117 
iTRAQ labeled samples in buffer A (20 mM NH4HCO2, pH 10) before High-Performance Liquid 118 
Chromatography (HPLC) on a Gemini-NX C18 columns (3 μm, 2 × 150 mm, 110 A, Phenomenex) 119 
with buffer A (mobile phase A), and buffer B (80% ACN/20% 20 mM NH4HCO2, mobile phase B). 120 
At a flow rate of 0.2 mL/min, the peptides were eluted with a gradient of 0%–5% mobile phase B for 121 
10 min, 5%–10% mobile phase B for 10 min, 15%–37% mobile phase B for 60 min, 37%–95% 122 
mobile phase B for 5 min, and 95% mobile phase B for 5 min. The UV absorbance was set at 214/280 123 
7 
 
nm to collect fractions every 1 min for 12 fractions per each sample. The fractions were dried for 124 
further analysis. 125 
 126 
2.5 LC-MS/MS Analysis 127 
The samples were separated by a linear gradient, which was formed by mobile phase A (0.1% FA, 128 
5% ACN) and mobile phase B (0.1% FA, 80% ACN). In 40 min, the mobile phase B was changed 129 
from 5% to 35% at a flow rate of 300 nL/min. We used a Triple TOF 5,600 system (AB SCIEX) with 130 
an information dependent mode to perform the Mass Spectrometer (MS) analysis. Using 100 ms 131 
accumulation time per spectrum, in high-resolution mode (70,000), we dynamically acquired MS 132 
spectra across the mass range of 350-1,800 m/z. Up to 20 precursors per cycle was selected for 133 
fragmentation from each MS spectrum, where each precursor has a minimum accumulation time of 134 
120 s and a dynamic exclusion of 20 s. The high sensitivity mode (resolution: 17,500) of tandem mass 135 
spectra were used, which has rolling collision energy and an iTRAQ reagent collision energy 136 
adjustment.  137 
 138 
2.6 Protein identification and data analysis 139 
Via Proteome Discoverer 1.4 (Thermo Fisher Scientific), the raw data were converted to peak lists, 140 
which are MASCOT generic format (.mgf) files. For in-depth proteome analysis and protein 141 
quantitation analysis, we searched the Uniprot-mouse database and the Uniprot-rat database 142 
(www.uniport.org) with the ProteinPilotTM Software 5.0 (Applied Biosystems Sciex). This software 143 
is based on Paragon Algorithm to convert the peptide analysis data into differential protein analysis 144 
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data (Unused > 1.3, Peptides（95%）≥ 2). To ensure up- and downregulation authenticity, a P-value 145 
< 0.05 and a fold change ≥ 2 (FC ≥ 2) and a FC ≤ 0.5 were used in the analysis. To understand the 146 
relationships between the mice and rats infected with T. gondii, we used Venn diagram 147 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) and DAVID (https://david.ncifcrf.gov) to 148 
compare the  DEPs and their biological functions. KEGG database was used for biological pathway 149 
analysis of these DEPs (http://www.genome.jp/kegg/), where every protein’s name, sequence and 150 
functional information are provided by UniProt Databases (http://www.uniprot.org/).  151 
 152 
2.7 Quantitative real-time PCR analysis  153 
We used quantitative real-time PCR (qRT-PCR) analysis to verify the expression of DEPs from the 154 
iTRAQ analysis. Using the manufacturer’s protocols of RNAiso Plus (TaKaRa, Dalian, China), total 155 
RNA was extracted from the infected and control KM mice’s and rats’ brains. Then, we resuspended 156 
the final total RNA into RNase-free water and measured its concentration and purity using the ultra-157 
microspectrophotometer (Thermo Scientific Nanodrop 2000, Waltham, MA, USA). cDNA was 158 
synthesized using the SYBR PrimeScript™ RT Master Mix (Perfect Real-Time) Kit (TaKaRa, Dalian, 159 
China). Gene-specific primers for qRT-PCR were designed with Premier 5.0 software (Premier 160 
Biosoft International, Palo Alto, CA, USA). According to the manufacturer’s instructions (TaKaRa 161 
Dalian, China), qRT-PCR was performed on a Rotor-Gene Q (Qiagen) real-time system with SYBR 162 
Green master mix (SYBR Premix Ex Tag TMII; TaKaRa Bio; http://www.TaKaRa-bio.com). The 163 
thermal profile of qRT-PCR was 5 min at 95ºC followed by 40 cycles of 30 s at 95ºC and 1 min at 164 
60ºC. Each sample was run in triplicates. For normalization of gene expression, we used β-actin as a 165 
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reference gene, and we established a blank control, which was set as 1. Relative gene expression was 166 
calculated by using the formula 2–△△Ct. 167 
 168 
3. Results 169 
3.1 Detection of differentially expressed proteins in mice and rats 170 
To find out the effects of T. gondii infection in the host brain at the protein level, we infected KM 171 
mice and SD rats with T. gondii Pru strain. We established an iTRAQ-based strategy to analyze the 172 
brains of mice and rats. On the basis of the analysis with ProteinPilotTM 5.0 search engine in the mice 173 
and rats respectively, we searched out 173,032 and 166,557 identified spectra, 80,329 and 76,902 174 
distinct peptides, 17,081 and 16,974 proteins before grouping, and 5,033 and 4822 proteins with a 175 
minimum unused score of > 1.3 (Unused > 1.3), which indicates > 95% confidence in correct 176 
sequence identification. In total, 4,862 and 4,659 proteins were acquired in mice and rats, respectively, 177 
with at least two peptides identified (Peptides ≥ 2). About 86.81% and 74.7% of these proteins had a 178 
coefficient of variation (CV) of ≤ 50% among replicates in the mice and rats, respectively. All data 179 
related to this study has been publicly available on iProX (www.iprox.org) with id IPX0001302000 180 
/PXD011192. The following analysis was based on proteins with CV ≤ 50%. In total, we determined 181 
461 DEPs (P < 0.05, FC ≥ 2, and FC ≤ 0.5) in infected mice, among them 215 were upregulated 182 
(46.63%), and 246 downregulated (53.37%). Whereas, in infected rats 292 DEPs were detected (P < 183 
0.05, FC ≥ 2, and FC ≤ 0.5), among them 95 upregulated (32.53%), and 197 downregulated (67.47%) 184 
(shown in supplementary information). Considering the names of mice’s proteins, which differ from 185 
rat’s, we used the “BLAST” software to find homogeneous DEPs (HDEPs), which included 381 186 
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proteins in KM mice and 269 in rats (Figure 1). These results suggested that the DEPs of our focus 187 
should be further narrowed so that the cerebral proteomic differences between rats and mice infected 188 
with T. gondii could be displayed more directly. In addition, further studies should be needed to verify 189 
the reliability of the DEPs. 190 
 191 
3.2 Validation of differentially expressed proteins by quantitative real-time PCR 192 
To determine the reliability of the iTRAQ results in mouse and rat, we selected 5 proteins with 193 
different expression level for qRT-PCR analysis. We found total agreement between the results of 194 
qRT-PCR and iTRAQ results (Figure 2). Data were statistically analyzed and were presented as a 195 
mean ± standard deviation. The differences in protein expression patterns could be possibly argued 196 
by the higher sensitivity of iTRAQ comparing to qRT-PCR suggesting that the iTRAQ results are 197 
more reliable.  198 
 199 
3.3 Complement component 3 upregulation in mice infected with T. gondii 200 
Because of the massive number of data, we had to reduce the amount of information if we wanted to 201 
make a differential analysis. To find the key proteins that differentiate the phenotypes of the two hosts, 202 
we firstly, compared the HDEPs from rats and mice (Figure 3a). Sixty-seven HDEPs were detected 203 
to be common to both two hosts, while 202 and 314 HDEPs were specific to SD rats and KM mice, 204 
respectively. To explore the mechanism of differential susceptibility, we therefore focused on the 205 
particular HDEPs. Subsequently, we further investigated biological functions of these HDEPs and 206 
mapped them into 71 pathways of rats, 37 pathways of KM mice and 28 homo-pathways using 207 
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DAVID database. Performing Venn analysis of all these pathways, we further narrowed the range of 208 
data to find specific protein pathways in rats and mice (Figure 3b). We focused only on specific 209 
pathways of typical HDEPs. We identified 10 mouse-specific pathways and 44 rat-specific pathways, 210 
of which the top 10 enriched pathways are shown in Figure 4. The top 10 enriched pathways of rats 211 
were Rap1 signaling pathway, Endocytosis, Neurotrophin signaling pathway, Cholinergic synapse, 212 
Alcoholism, Ras signaling pathway, Chemokine signaling pathway, GnRH signaling pathway, 213 
Melanogenesis, and Alzheimer's disease. Whereas, the top 10 enriched pathways of mice were Protein 214 
processing in endoplasmic reticulum, TJ, Complement and coagulation cascades, Parkinson’s disease, 215 
Platelet activation, Glutathione metabolism, Phosphatidylinositol signaling system, Bacterial 216 
invasion of epithelial cells, Amoebiasis, and Staphylococcus aureus infection. Upon infection, the 217 
parasites persist as intraneuronal cysts in the CNS for the lifetime of the host[7]. Interestingly, the T. 218 
gondii cysts are more frequently found in the brain of mice than in the brain of rats[9, 12]. The control 219 
of cysts depends on the immune system of hosts, and the ongoing inflammation is required to control 220 
T. gondii in chronic cerebral infection[7]. The complement system contributes to the defense of 221 
infection, as an important aspect of host immune system[17]. Additionally, the brain invasion of T. 222 
gondii relates to TJ[18]. Consequently, we considered that the primary cause of the phenotypic 223 
difference between mouse and rat may be associated to the immune system and the brain invasion of 224 
T. gondii. So we focused on the complement and coagulation cascades pathway and TJ, which had 9 225 
and 10 DEPs, respectively (Table 1 and 2). The most significant HDEP among them was C3 therefore, 226 
these results suggested that the C3 protein may be a crucial protein that differentiate the phenotype 227 
of the two hosts. 228 
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 229 
4. Discussion 230 
In this study, we infected rats and mice with type II T. gondii strain (Pru). We then used an iTRAQ-231 
based strategy to identify 381 HDEPs in rats’ brain and 269 in KM mice’s brains (Figure 1). By using 232 
the KEGG pathway analyses, we specifically found the complement-related pathway and TJ pathway 233 
in the infected mice’s brains, which contained 19 HDEPs. Among them, expression of C3 was 234 
increased 11 times as compared with the control group (Table 1 and 2). 235 
 236 
Strain type, host genetic background, and route of infection contribute obviously to the differential 237 
susceptibility to T. gondii infection[19]. Because of the differences in the virulence and geographical 238 
occurrence, this parasite contains three major types: I, II, and III[19, 20] . Type II strains are the most 239 
prevalent in the United States and Europe[21]. Mice are good models for T. gondii due to their high 240 
sensitivity to many different strains[8]. Type I T. gondii strains can lethally infect mice, while type II 241 
and III strains cause chronic-progressive or latent infection [2, 22]. Comparatively, rats are more 242 
resistant to toxoplasmosis and mimic T. gondii disease in human[8]. Type I, type II and III strains 243 
cause chronic subclinical infection in immunocompetent rats[9, 10, 23-25], but the pathology and 244 
physiology of T. gondii infection in rats are still poorly understood[11]. Taken together, type II strains 245 
are appropriate experimental materials to study the different outcome of T. gondii infection in mice 246 
and rats.  247 
 248 
Scientists attribute the increasing understanding of T. gondii protein expression to the advances of 249 
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proteomic technologies. Using 2-dimensional electrophoresis (2-DE) and matrix-assisted laser-250 
desorption/ionization time of flight mass spectrometry (MALDI- TOF-MS), Cohen et al. constructed 251 
the first proteome map of T. gondii tachyzoite in 2002[26]. Recently, Zhou et al. used the same strategy 252 
to observe the proteomic changes in the hippocampus tissue of rat brain with chronic T. gondii 253 
infection[27]. Furthermore, Zhou et al. explored the proteomic profiles of brain tissues of KM mice at 254 
7, 14, 21 d after infection with Pru strain cysts[28]. Some researchers used two-dimensional difference 255 
gel electrophoresis (2D-DIGE) and MALDI-TOF-MS to identify DEPs of 4 different genotypes of T. 256 
gondii tachyzoites [29]. In recent years, iTRAQ was reported to be the most accurate labeling method 257 
for quantification of the relative abundance of proteins with good accuracy and repeatability[30]. 258 
Because of its high-throughput, it has been widely used in proteomics to study the relative and 259 
absolute quantification of up to 8 samples at the same time[30]. Sahu et al. firstly utilized iTRAQ 260 
labeling for a global quantitative proteomic study of the proteome profile of human brain that was 261 
co-infected with T. gondii and HIV[31]. Later, the liver proteome of the mouse following acute T. 262 
gondii infection and the proteome of T. gondii oocysts during sporulation were reported[32]. 263 
Interestingly, Wang et al. compared DEPs from different stages of T. gondii Pru strain, including 264 
tachyzoite, bradyzoites-containing cyst, and sporulated oocyst[33]. Moreover, we have previously 265 
reported the DEPs of Mongolian gerbil brains infected with T. gondii[34]. Notably, the new research 266 
technology of iTRAQ has provided improvements in three aspects: high throughput, sensitivity and 267 
accuracy[35]. With the advancement of the technology, iTRAQ is still widely used in bio-materials 268 
such as microbes, animals, plants and biomedicine[36]. Most importantly, iTRAQ-based strategy has 269 
been used for the identification of biomarkers in a plethora of diseases[37]. A recent study, validated 270 
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the role of CD44 in hosts chronically infected with T. gondii based on iTRAQ technology, and 271 
reported that CD44 mediates the production of IFN-γ and Ca2+, and the parasite prefers to invade 272 
cells with high levels of CD44[38]. In brief, this is the first study to establish an iTRAQ-based strategy 273 
to compare DEPs from infected rats’ and KM mice’s brains, which aimed to explore the mechanism 274 
of different susceptibility of mice and rats to T. gondii. 275 
 276 
T. gondii can infect a variety of tissues including the brain, and because of preference for the neurons, 277 
it results in Toxoplasma encephalitis (TE)[7]. TE, characterized by both focal and diffuse neurological 278 
lesions, concurs with behavior disorders and mental symptoms, such as schizophrenia, Alzheimer’s 279 
disease (AD) and Parkinson’s disease (PD)[39]. In agreement, T. gondii-infected rodents exhibit a 280 
number of modifications in their behavior. For example, T. gondii causes a shift in the emotional 281 
response of rats and increases the timidity in mice[24, 40]. Most notably, they display an altered 282 
response to feline predator odor, from aversion to attraction[23, 41]. At present, the proposed hypotheses 283 
of TE pathogenesis include host dopamine pathways, direct damages to neurons, and parasite-284 
mediated acetylation[7, 42], but the mechanisms explaining how T. gondii exactly affects the CNS are 285 
not precisely demonstrated. During T. gondii chronic infection, the cysts persist in the CNS for the 286 
life time of the host[43]. The changes observed in the hosts with T. gondii on the CNS are related to 287 
the tissue cyst tropism, size and number[44]. Compared to rats, the behavioral disorders of mice are 288 
much more conspicuously affected by a T. gondii-infection[14]. Because of the interest in behavioral 289 
effects of hosts infected with T. gondii, several authors have claimed that the parasite shows a tissue 290 
tropism for the amygdalar region in the brains of chronically infected rodents [23, 24, 45]. However, 291 
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amygdala tropism is not clear for tissue cysts in rats [11]. In addition,  some previous studies in mice 292 
reported that tissue cysts are distributed unevenly in all regions of the brain with no specific tropism 293 
to amygdaloid regions[13]. But other studies indicated that tissue cyst distribution is not random and 294 
tropism could vary with the duration of infection[44, 46]. Dubey et al. (2016) indicated that these 295 
differences of tissue cyst tropism are related to techniques, host, parasite strain, route of infection, 296 
duration of infection, number of rodents, method of infection and development stage of the parasite[11]. 297 
Consequently, in order to avoid tropism differences between mice and rats to influence the proteomic 298 
results, we used the same parasite strain (Pru) freshly collected in one mouse, infected animals 299 
through the same way (oral), and included the whole brain of each experimental animal after 30 days 300 
of infection. Dubey et al. (2016) added that the tissue cyst size is dependent on the duration of 301 
infection, the type of host cell parasitized, development strain of the parasite and the cytological 302 
method used for measurement[11]. When both hosts are given the same inoculum, tissue cysts in brains 303 
of rats are of the same size as in mice[25]. However, the T. gondii cysts are abundantly found in the 304 
brain of mice but less frequently found in the brain of rats[9, 12]. According to a research on reactivation 305 
of latent infection, T. gondii tachyzoites are present in the brains of chronically infected mice but the 306 
frequency of the phenomenon is unknown[47]. Instead, in experimentally infected rats, tissue cyst 307 
rupture was frequent, but there was no evidence for reactivation and the presence of tachyzoites[11]. 308 
Moreover, the rats have lower brain infestation and no visible histological damages[12, 13]. These 309 
phenomena of T. gondii infection brought us to consider what differences exist between rat and mouse 310 
brain. 311 
 312 
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The infiltrating peripheral immune cells in the CNS provide a continuous immune response to prevent 313 
TE and avoid reactivation of TE[48]. Since the 1980s, some researchers have shown that the 314 
complement pathway is either a critical response factor for an initial immune response to T. gondii 315 
or a target for parasite evasion[49]. These observations support that complement pathways are 316 
particularly changed in the KM mice brain with T. gondii infection, unlike in rats, and it may explain 317 
at least partially why mice and rats have different susceptibility to T. gondii infection. Previous 318 
reports showed that C1q, C3, and C4b are upregulated in some brain disorders associated with TE, 319 
including schizophrenia, AD, aging and multiple sclerosis[34, 50, 51]. In the current study, we identified 320 
several pathways, like the AD in the rat and PD in the mice (Figure 4), which is in agreement with 321 
the previous studies. Although Xiao et al. (2016) have reported alterations in the level of C1q in 322 
mice[52], this is the first study that directly identified C1q, C3, and C4b from the brain of infected KM 323 
mice. 324 
 325 
Complement is an innate immune system pathway recognizing and eliminating cellular debris and 326 
pathogens. Among them, C1q is a part of the C1-complex and is an immune protein that bridges 327 
adaptive and innate immunity. The basic functions of C1q are to clear antigen-antibody immune 328 
complexes in systemic circulation [53]. Furthermore, C1q initiate the proteolytic reactions to generate 329 
molecules, which participate in phagocytic responses and inflammation, and induce the activation of 330 
the classical complement pathway [17]. In the classic immune responses, C1q leads to activation of 331 
C3 and cleaves C3 into C3a and C3b, which is a central protein in the complement and coagulation 332 
cascade[54]. C3a can promote inflammatory responses and gliosis, which is an anaphylatoxin. C1q 333 
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and C3b fragments can bind to the surface proteins of microorganisms to promote phagocytosis[55]. 334 
Additionally, C1q-C3 can modulate the expression of the interleukin 1 beta (IL1β) and tumor necrosis 335 
factor alpha (TNFα), and the hyperplasia of microglia and astrocytes[56, 57], after SE or in epilepsy[58]. 336 
Considering studies on the classical complement pathway in T. gondii infection using quantitative 337 
PCR, Xiao et al. (2016) firstly claimed that C1q activation is a part of the host immune response to 338 
T. gondii chronic infection, and primarily recognizes degenerate cysts as targets for the parasite 339 
elimination[52]. In our study, we used iTRAQ strategy to confirm the variation of C1q in the KM mice 340 
with T. gondii infection. As a factor for SE or epilepsy, the T. gondii increases C1q and C3 in the host 341 
brain, which may remarkably contribute to the neurogenic inflammation. 342 
 343 
For non-inflammatory mechanisms, on the one hand, microglia express complement receptors, and 344 
C1q, while C3 locate synapses, which collectively mediate phagocytic microglia to prune synapses 345 
in developing brains[59]. However, this process is significantly down-regulated in the mature brain[59]. 346 
C4 also is a crucial part of the complement cascade, which is expressed by neurons and is secreted 347 
by dendrites, axons and synapses[51]. During postnatal development, C4 promotes synapse 348 
elimination in mice[59]. Accordingly, C4 activity in the event of schizophrenia will reduce the number 349 
of synapses[51, 60]. Emerging research implicates activation of the synaptic pruning pathway in 350 
synapses loss in the AD brain[61]. Accordingly, we hypothesized that by increasing C1q, C4b, and C3 351 
expression, chronic T. gondii infection mediates damage of nerve cells, such as neurodegeneration, 352 
possible synapse loss, and neuronal death. On the other hand, C1q and iC3b proteins can mediate 353 
phagocytic responses of microglia, which consequently, means that C1q and iC3b attract microglia 354 
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to the orchestrate elimination of foreign bodies, called as “eat-me” signals [17, 62]. To illustrate, C1q 355 
binds to cellular debris or apoptotic cells to promote microglial clearance and prevent further 356 
inflammation[56, 63]. Therefore, some researchers reported that the activation of complement protects 357 
nerve cells in epilepsy and SE[64]. For T. gondii infection, this mechanism may protect the nerve cells 358 
as well. In conclusion, the complement is a two-edged weapon, which can be beneficial and 359 
detrimental for the host when T. gondii infects the brain. 360 
 361 
The basal lamina, pericytes, endothelial cells and astrocytic end-feet comprise the BBB, which is a 362 
selective barrier. The tight junctions in the BBB are adhesive structuresthat seal the gap between 363 
endothelial cells to selectively prevent the  entry into the brain of pathogenic microbes and antigens 364 
from the blood[65]. Pathogens must cross the BBB to enter the CNS, which is a challenge[66]. A 365 
plausible explanation for the development of TE is that some T. gondii tachyzoites enter the CNS and 366 
form into cysts to avoid the host immune responses and anti-toxoplasma drugs. Nevertheless, how 367 
does T. gondii cross TJs to enter the brain? Two mechanisms have been proposed. The first one is the 368 
transcellular crossing mechanism, in which tachyzoites from the bloodstream can adhere to, invade, 369 
replicate and pass from the endothelial cells of CNS to the CNS parenchyma. This mechanism was 370 
discovered by utilizing multiphoton in vivo imaging and transgenic reporter systems (Figure 5B) [6]. 371 
Although the parasite infection of the CNS precedes immune cells infiltration[67], some studies 372 
reported that mouse brain is more quickly infected by dendritic cells and macrophages previously 373 
infected with T. gondii tachyzoites than by T. gondii tachyzoites only[68]. This findings are in 374 
agreement with a second mechanism called the Trojan-horse like mechanism, which implicates 375 
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infected immune cells as a carriers of the intracellular parasites through the BBB (Figure 5A)[5, 68]. In 376 
addition, we thought of a third mechanism in which T. gondii tachyzoites may directly cross the BBB 377 
through the brain TJ (Figure 5C). Previous studies have described that the T. gondii tachyzoites can 378 
show “gliding motility”, which can help the parasites to go across the epithelium of the small 379 
intestine[69]. Inspiringly, under shear force conditions tachyzoites can adhere to the human vascular 380 
endothelium to increase the invasive percentage[70]. These lines of evidence prompted us to wonder 381 
if T. gondii crosses the BBB via the intercellular space. Some scholars named it as ‘paracellular entry’ 382 
[71], but until now, no study presented direct evidence to support it. 383 
 384 
We hypothesized that T. gondii disrupts the TJ of BBB and allows T. gondii to pass into the brain by 385 
paracellular entry, in which C3 plays a crucial role. Previous studies reported that C3 disrupts the 386 
renal tubules barrier to develop proteinuria [72, 73]. In brains, blood-cerebrospinal fluid (CSF) barrier 387 
is as vital as the BBB, where the choroid plexus epithelial (CPEpi) cells represent an essential 388 
component of this barrier. Additionally, the CPEpi cells express the C3a receptor (C3aR) of C3, 389 
which is a G protein-coupled receptor[74]. Moreover, myosin light-chain kinase (MLCK) is a key 390 
regulator of TJ permeability, and by the addition of C3a, it transiently increases its phosphorylation 391 
[75].  C3a was proved by immunofluorescence to be able to disorganize the TJ of mouse CPE. This 392 
effect of C3a was also found in the renal and pulmonary epithelia[73, 76]. It represents one line of 393 
evidence for our hypothesis of the involvement of TJ pathway in KM mouse brain during T. gondii 394 
infection. Transmembrane proteins compose TJs, including occludins, claudins, and intracellular 395 
proteins, which maintain the integrity of the BBB. These intracellular proteins contain ZO-1, ZO-2 396 
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and ZO-3 [77] [78]. Moreover, Protein kinase C (PKC) is essential for the normal assembly of TJs. PKC 397 
affects the opening of TJs and plays a role in decreasing and increasing the permeability of TJ[79]. 398 
Phorbol 12-myristate 13-acetate as an agonist of PKC can lead to the TJs disintegration [80]. Persistent 399 
activation of PKCα decreases the expression of TJ proteins and increases the BBB permeability, 400 
which means that the barrier function is lost [81]. In this study, the TJ pathway, and majority of HDEPs 401 
were down-regulated such as the PKC, however a few HDEPs were up-regulated; TJ protein zonula 402 
occludens-2 (ZO-2) was one of them. This up-regulation may be a compensatory effectof the TJ 403 
damage caused by T. gondii infection, which induces the PKC down-regulation to stimulate the 404 
secretion of TJ protein, in order to restore the TJ functionality. 405 
 406 
In other contexts, the pharmacologic interventions of complement cascade especially in C3 has been 407 
explored such as autoimmune arthritis[82] and reactive airway disease[83]. Our findings elicit lots of 408 
significant questions for further studies. Complement C3 manipulation of the BBB integrity might be 409 
employed to allow for increased access of T. gondii into the CNS. Further preclinical studies could 410 
make this hypothesis possible. 411 
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 Table 1: HDEPs of the complement and coagulation cascades pathway in the infected mice’s brain. 
Protein Gene 
symbol 
Description Toxoplasma 
encephalistis/Control 
(Fold change) 
Plasminogen Plg Plasmin is an important enzyme present in blood that degrades many blood plasma proteins, including fibrin clots. The degradation of fibrin is termed 
fibrinolysis.  
5.032887165 
Antithrombin-III Serpinc1 AT III is generally referred to solely as "Antithrombin", which is a small protein molecule that inactivates several enzymes of the coagulation system.  3.018619571 
Fibrinogen beta chain Fgb Fibrinogen beta chain, also known as FGB, is a gene found in humans and most other vertebrates with a similar system of blood coagulation.The protein 
encoded by this gene is the beta component of fibrinogen, a blood-borne glycoprotein composed of three pairs of nonidentical polypeptide chains. Following 
vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots.  
6.43841143 
Fibrinogen alpha chain Fga The protein encoded by this gene is the alpha component of fibrinogen. 3.565736133 
Coagulation factor XIII A 
chain 
F13a1 Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A 
subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier 
molecules.  
4.641328363 
Alpha-2-macroglobulin-P A2m Alpha 2 macroglobulin acts as an antiprotease and is able to inactivate an enormous variety of proteinases. It functions as an inhibitor of fibrinolysis by 
inhibiting plasmin and kallikrein. It functions as an inhibitor of coagulation by inhibiting thrombin.  
10.46278151 
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Complement C3 C3 Complement component 3, often simply called C3, is a protein of the immune system. It plays a central role in the complement system and contributes to 
innate immunity.  
11.06623745 
Complement C4-B C4b Complement component 4, in humans, is a protein involved in the intricate complement system, originating from the human leukocyte antigen (HLA) 
system. It serves a number of critical functions in immunity, tolerance, and autoimmunity with the other numerous components.  
9.375619888 
Complement C1q 
subcomponent subunit A 
C1qa The C1q complex is a protein complex involved in the complement system, which is part of the innate immune system. C1q is part of the C1-complex. 5.649369717 
28 
 
Table 2: HDEPs of the Tight junction pathway in the infected mice’s brain. 
Protein Gene symbol Toxoplasma 
encephalistis/Control 
(Fold change) 
Description 
Tight junction protein ZO-2 Tjp2 4.23769481 Tight junction protein ZO-2 plays a role in tight junctions and adherens junctions. It has a role as a scaffold protein 
which cross-links and anchors Tight Junction (TJ) strand proteins, which are fibril-like structures within the lipid 
bilayer, to the actin cytoskeleton. 
Protein kinase C Prkca 0.403918909 Protein kinase C modulates membrane structure events. 
Protein kinase C gamma type Prkcg 0.314442886 
Ras-related protein Rab-3B Rab3b 0.408556377 Ras-related protein Rab-3B plays a role in protein transport. 
Alpha-actinin-2 Actn2 0.44870987 As a bundling protein, it is thought to anchor actin to a variety of intracellular structures. 
Myosin-9 Myh9 7.139545535 Myosins comprise a superfamily of ATP-dependent motor proteins and are best known for their role in muscle 
contraction and their involvement in a wide range of other motility processes in eukaryotes. Virtually all eukaryotic 
cells contain myosin isoforms. During cell spreading, myosin-9 plays an important role in cytoskeleton reorganization, 
focal contacts formation. 
Myosin-10 Myh10 0.355443681 
Myosin-11 Myh11 0.228766571 
Protein Shroom2 Shroom2 0.389755496 Shroom2 is both necessary and sufficient to govern the localization of pigment granules at the apical surface of 
epithelial cells. It is possible that SHROOM2 mutations may contribute to human visual system disorders. 
Catenin alpha-1 Ctnna1 2.592327188 Catenin alpha-1 associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to 
cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary 
importance for cadherins cell-adhesion properties.  
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Fig. 1. Heat map of HDEPs. The HDEPs with a fold change of ≥ 2-fold or ≤ 2-fold and p ≤
0.05 are shown in the heat map, which include 381 proteins in rats and 269 in KM mice. 
Upregulation is displayed by orange color and downregulation is displayed by blue color.  
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Fig. 2. The fold change in mRNA expression, detected by qRT-PCR. The clustered columns 
show that the expression patterns of 10 selected proteins detected by qRT-PCR were consistent 
with those obtained by iTRAQ. (a) The clustered column shows the expression patterns of the SD 
rats’ selected proteins. (b) The clustered column shows the expression patterns of the KM mice’s 
selected proteins. Error bars represent SEM. 
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Fig. 3. Comparison of the HDEPs. (a) Venn diagrams of HDEPs between SD rats’ and KM mice’ 
brain. Proteins with base mean fold change ≥ 2 or ≤ 2, and p < 0.05 were collected for analysis.  
(b) By using the KEGG database, we investigated biological functions of these HDEPs and mapped 
them to 93 pathways in total. Venn diagrams of pathways of HDEPs between SD rats’ and KM 
mice’ brain; p < 0.01 were collected for each pathway. 
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Fig. 4. The most enriched pathways of HDEPs. The clustered column shows the top 10 enriched 
pathways of typical HDEPs from KM mice and the other 10 of typical HDEPs from SD rats.  
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Fig. 5. The routes of T. gondii’s brain infection. (A) Trojan-horse like mechanism: The infected 
immune cells bring the intracellular parasites through the BBB. (B) Transcellular crossing 
mechanism: The bloodstream tachyzoites adhere to, invade in, replicate at, and pass from the 
endothelial cells of CNS to enter the CNS parenchyma. (C) Paracellular entry mechanism: 
Cooperating with C3 the bloodstream tachyzoites may directly cross the BBB through the brain TJ. 
 
 
